Interesting graphical retracement for the Amgen stock which sees a considerable decline from the highs of the year. Where does the caution stem from? First, management highlighted that new patient prescriptions remain below pre-COVID-19 levels, and second, variants are suggesting demand may be muted for now. The stock has a solid capital appreciation potential and dividend growth prospects out to 2024-2026. Annual Profit: 9.5 bil $ Total debt: 32.7 bil $
IMPORTANT:
Please remind yourself that this is just my personal view on the market. My analysis should NOT serve as any recommendation to buy or to sell.
Always make your analysis of your own before your trade.
If you find useful my analysis, please hit the LIKE button and follow me.
Please remind yourself that this is just my personal view on the market. My analysis should NOT serve as any recommendation to buy or to sell.
Always make your analysis of your own before your trade.
If you find useful my analysis, please hit the LIKE button and follow me.